1

Circulating metabolic biomarkers are consistently associated with incident type 2 diabetes in Asian and European populations – a metabolomics analysis in five prospective cohorts

Jowy Yi Hoong Seah^{1*}, Yueheng Hong^{1*}, Anna Cichońska^{2*}, Charumathi Sabanayagam^{3, 4}, Simon Nusinovici³, Tien Yin Wong^{3, 4, 5}, Ching-Yu Cheng^{3, 4, 5}, Pekka Jousilahti⁶, Annamari Lundqvist⁶, Markus Perola^{6,7}, Veikko Salomaa⁶, E. Shyong Tai^{1, 4, 5}, Peter Würtz², Rob M. van Dam^{1, 8†}, Xueling Sim^{1†}

¹Saw Swee Hock School of Public Health, National University of Singapore and

National University Health System, Singapore; Singapore 117549, Singapore

²Nightingale Health Ltd, Mannerheimintie 164a, 00300 Helsinki, Finland

³Singapore Eye Research Institute, Singapore National Eye Centre, Singapore

169856, Singapore

⁴Duke-NUS Medical School, Singapore 169857, Singapore

⁵Yong Loo Lin School of Medicine, National University of Singapore and National

University Health System, Singapore 117597, Singapore

⁶Department of Public Health Solutions, Finnish Institute for Health and Welfare,

P.O. Box 30, FI-00271 Helsinki, Finland

⁷Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,

University of Helsinki, 00014 Helsinki, Finland.

⁸Departments of Exercise and Nutrition Sciences and Epidemiology, Milken Institute

School of Public Health, The George Washington University, Washington, DC 20052.

*These authors contributed equally.

†These authors are co-corresponding senior authors.

2

Rob M. van Dam. Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, 950 New Hampshire Ave NW, Washington, DC 20052; tel: +1 202 994 8490; e-mail: rvandam@gwu.edu Xueling Sim. Saw Swee Hock School of Public Health, 12 Science Drive 2, #10-01, Singapore 117549; tel: +65 6601 5096; e-mail: <u>ephsx@nus.edu.sg</u>

Number of figures (to print, not Supplementary data): 1

Number of tables (to print, not Supplementary data): 2

Supplementary data submitted: 6 tables

Running title: Metabolic biomarkers and type 2 diabetes

Abbreviations: ARIC, Atherosclerosis Risk in Communities, BCAA, branched-chain

amino acids, BMI, body mass index, GlycA, glycoprotein acetyls, HbA1c, glycated

hemoglobin, HDL, high-density lipoprotein, IDL, intermediate-density lipoprotein,

LDL, low-density lipoprotein, MEC, Multiethnic Cohort, MUFA, monounsaturated

fat, NMR, nuclear magnetic resonance, PUFA polyunsaturated fat, SEED, Singapore

Epidemiology of Eye Diseases, SFA, saturated fat, T2D, type 2 diabetes, VLDL, very low-density lipoprotein

Word count: 4229 (Introduction to Discussion)

1 Abstract

- 2 Background: While Asians have a higher risk of type 2 diabetes (T2D) than
- 3 Europeans for a given BMI, it remains unclear whether the same markers of metabolic
- 4 pathways are associated with diabetes.
- 5 Objectives: We evaluated associations between metabolic biomarkers and incident
- 6 T2D in three major Asian ethnic groups (Chinese, Malay, and Indian) and a European
- 7 population.
- 8 Methods: We analyzed data from adult males and females of two cohorts from
- 9 Singapore (n = 6,393) consisting of Chinese, Malays and Indians, and three cohorts of
- 10 European-origin participants from Finland (n = 14,558). We used nuclear magnetic
- 11 resonance to quantify 154 circulating metabolic biomarkers at baseline and performed
- 12 logistic regression to assess associations with T2D risk adjusted for age, sex, BMI and
- 13 glycaemic markers.
- 14 Results: Of the 154 metabolic biomarkers, 59 were associated with higher risk of T2D
- 15 in both Asians and Europeans (P < 0.0003; Bonferroni-corrected). These included
- 16 branched-chain and aromatic amino acids, the inflammatory marker glycoprotein
- 17 acetyls, total fatty acids, monounsaturated fatty acids, apolipoprotein B, larger very
- 18 low-density lipoprotein particle sizes, and triglycerides. In addition, 13 metabolites
- 19 were associated with a lower T2D risk in both populations including omega-6
- 20 polyunsaturated fatty acids and larger high-density lipoprotein particle sizes.
- Associations were consistent within the Asian ethnic groups (all $P_{het} \ge 0.05$) and
- 22 largely consistent for the Asian and European populations ($P_{het} \ge 0.05$ for 128 of 154
- 23 metabolic biomarkers).
- 24 Conclusion: Metabolic biomarkers across several biological pathways were
- 25 consistently associated with T2D risk in Asians and Europeans.

- 27 Keywords: NMR, metabolomics, type 2 diabetes, branched-chain amino acids,
- aromatic amino acids, glycoprotein acetyls, inflammation, fatty acids, lipoprotein,
- HDL, LDL, triglycerides, cholesterol
- 30

31 Introduction

32	The global burden of type 2 diabetes (T2D) is high and rising [1, 2], with the
33	prevalence expected to rise to 7079 cases per 100,000 in 2030, from 6059 cases per
34	100,000 in 2017 [2]. In randomized trials, pharmaceutical and lifestyle interventions
35	substantially reduced the risk of T2D [3-5] in high-risk individuals. Variation in
36	genetic, environmental and lifestyle exposures between individuals, coupled with
37	heterogeneity in T2D [6, 7] has motivated omics biomarkers as intermediate
38	phenotypes to T2D and the development of 'precision medicine' approaches to
39	prevention [8-10]. Metabolic biomarkers reflect the dynamic and ongoing state of
40	homeostasis and metabolism [11]. In recent years, the field of metabolomics has
41	gained traction due to technological advances [12] and has uncovered various
42	metabolites that are consistent predictors of T2D [13]. As many of these metabolic
43	biomarkers are modifiable by diet or other lifestyle factors, information on metabolic
44	risk factors may guide personalized interventions.
45	
46	Previous studies on metabolic profiles and T2D risk were mostly conducted in
47	populations of predominantly European ancestry, and it remains unclear if these

48 findings can be generalized to different Asian ethnic groups. For example, individuals

49 of Asian origin tend to develop T2D at a lower body mass index (BMI) and a younger

50 age than those of European origin [7], and ethnic Indians are generally more insulin

resistant than ethnic Malays or Chinese [14]. Although some metabolomics studies on
T2D incidence have been conducted in East Asian (e.g. Chinese) populations, data on

53 South East Asian (e.g. Malays) and South Asian (e.g. Indians) populations are limited

54 [13].

56	We therefore evaluated whether associations between biomarkers reflecting a variety
57	of biological pathways and diabetes incidence differed between Asian and European
58	ethnic groups. We quantified amino acids, an inflammatory marker, fatty acids,
59	lipoprotein and ketone bodies using nuclear magnetic resonance (NMR) metabolomic
60	analysis in two multi-ethnic cohorts in Singapore and three cohorts in Finland. NMR
61	metabolomics allows for highly reproducible identification and quantification of
62	compounds [15, 16]. We subsequently performed association analyses of these
63	metabolic measures with risk of T2D in three major Asian ethnic groups (Chinese,
64	Malay, and Indian) and the European population.
65	
66	Methods
67	Study Population
68	The Asian participants included in this study were from two population-based cohorts
69	in Singapore that included ethnic Indians, Malays and Chinese: the Multiethnic
70	Cohort (MEC) [17] study and the Singapore Epidemiology of Eye Diseases (SEED)
71	conort (while) [17] study and the singapore lipidennology of Lye Diseases (SELD)
71	cohort study [18, 19]. The European participants in our study were from three Finnish
71	
	cohort study [18, 19]. The European participants in our study were from three Finnish
72	cohort study [18, 19]. The European participants in our study were from three Finnish prospective population-based cohorts (FINRISK 2002, FINRISK 2012 and Health
72 73	cohort study [18, 19]. The European participants in our study were from three Finnish prospective population-based cohorts (FINRISK 2002, FINRISK 2012 and Health 2000) [20, 21]. All studies included questionnaires about socio-demographic
72 73 74	cohort study [18, 19]. The European participants in our study were from three Finnish prospective population-based cohorts (FINRISK 2002, FINRISK 2012 and Health 2000) [20, 21]. All studies included questionnaires about socio-demographic characteristics and medical history, technician-measurement of anthropometric
72 73 74 75	cohort study [18, 19]. The European participants in our study were from three Finnish prospective population-based cohorts (FINRISK 2002, FINRISK 2012 and Health 2000) [20, 21]. All studies included questionnaires about socio-demographic characteristics and medical history, technician-measurement of anthropometric measures and blood pressure, and collection of blood samples. Details of the
72 73 74 75 76	cohort study [18, 19]. The European participants in our study were from three Finnish prospective population-based cohorts (FINRISK 2002, FINRISK 2012 and Health 2000) [20, 21]. All studies included questionnaires about socio-demographic characteristics and medical history, technician-measurement of anthropometric measures and blood pressure, and collection of blood samples. Details of the individual cohorts are provided in the Supplemental Text . Informed consent was

7

80	For all cohorts, we excluded participants with diabetes, cardiovascular diseases or
81	cancer at baseline. From the MEC cohort of 9180 participants, we identified 694
82	incident diabetes cases using the following criteria: (a) fasting plasma glucose \geq 7.0
83	mmol/L or HbA1c \geq 6.5 % (47.5 mmol/mol) based on the American Diabetes
84	Association [22] or self-reported physician-diagnosed diabetes at follow-up, or (b)
85	record linkage with a national database of medical diagnoses as part of public
86	hospital, polyclinic, and subsidized GP visits). Using risk-set sampling, we selected
87	1315 controls matched for age (\pm 5 years), sex, date of health screening (\pm 2 years),
88	and ethnicity from cohort participants who were alive, and did not have diabetes at the
89	time the index case occurred. We used 6-year revisit data from 4384 SEED cohort
90	participants among whom 391 developed diabetes during follow-up. Diabetes
91	ascertainment at baseline and the revisit was based on random glucose $\geq 11.1 \text{ mmol/L}$
92	or HbA1c \geq 6.5 % (47.5 mmol/mol) [22], or a self-reported physician diagnosis. For
93	the European cohorts, we used data on 14588 participants from FINRISK 2002,
94	FINRISK 2012 and Health 2000, among whom 1055 developed diabetes during
95	follow-up. Diabetes ascertainment at baseline was based on the National Social
96	Insurance Institution Drug Purchase and Reimbursement Registries for purchases and
97	reimbursements of purchases of hypoglycemic drugs, and the National Hospital
98	Discharge Register for hospitalizations with diabetes as the diagnosis. Incident
99	diabetes cases were identified by linking the participants to the registers described
100	above with a unique personal identification code assigned to each Finnish citizen.
101	Participants with prevalent or incident gestational diabetes were excluded.
102	
103	Metabolic Biomarker Quantification and Quality Control

103 Metabolic Biomarker Quantification and Quality Control

8

104	Metabolic biomarkers were quantified from plasma (MEC, SEED Malays and
105	European cohorts) and serum (SEED Chinese and SEED Indians) samples at baseline
106	using a high-throughput ¹ H-NMR metabolomics platform developed by Nightingale
107	Health Ltd. (Helsinki, Finland; nightingalehealth.com/; biomarker quantification
108	version 2016). Details of the procedure have been described previously [23, 24]. The
109	metabolic biomarkers quantified reflected several etiologically diverse pathways, such
110	as amino acids, fatty acids, ketone bodies, and gluconeogenesis I related
111	measurements. In addition, lipoprotein measures including total concentration, total
112	lipids, phospholipids, total cholesterol, cholesterol esters, free cholesterol and
113	triglycerides within 14 lipoprotein subclasses were measured. 9 MEC and 20 SEED
114	participants had >10% missing metabolic biomarker values and were excluded from
115	subsequent analyses. For participants with metabolic biomarker values lower than
116	detection level, we replaced values of 0 with a value equivalent to 0.9 multiplied by
117	the non-zero minimum value of that measurement. Finally, we standardized the
118	metabolic biomarker concentrations to z-scores, and all effect sizes were reported as
119	per standard deviation increment to enable comparison of metabolic biomarker
120	associations for measures with different units and concentration ranges. A total of 154
121	individual metabolic biomarkers were included in our analyses.
122	

123 Statistical analyses

124 We first calculated Pearson's correlation coefficients for all 154 metabolic

125 biomarkers. Logistic regression was then used to assess associations between

126 circulating metabolic biomarkers with T2D. We did not use Cox regression because

127 most of the T2D cases were detected during revisit and the time-to-event data

128 therefore did not accurately reflect time from baseline to disease onset. For the

129	matched MEC case-control study, conditional logistic regression model was used. In
130	all studies, we adjusted for baseline age, sex, BMI, and fasting glucose (for MEC and
131	Health 2000) or glycated hemoglobin (HbA1c, for non-fasting SEED, FINRISK 2002
132	and 2012 cohorts). For MEC, age ² was included in the conditional logistic model as
133	there was evidence of non-linearity in the relationship between age and T2D risk.
134	Logistic models were performed separately by study and ethnic group to account for
135	differences between populations. Inverse variance-weighted fixed-effect meta-
136	analysis was used to first pool ethnic-specific association statistics from the two
137	Singapore cohorts, and then to combine association results from three ethnic groups.
138	We also tested for heterogeneity using the Cochran Q heterogeneity. Bonferroni
139	correction was used to account for multiple testing of 154 metabolic biomarkers and P
140	<0.0003 (0.05/154) was considered statistically significant.
141	
141 142	To test the joint effects of multiple metabolic biomarkers on risk of T2D, we first
	To test the joint effects of multiple metabolic biomarkers on risk of T2D, we first performed the variable selection as described below and subsequently included the
142	
142 143	performed the variable selection as described below and subsequently included the
142 143 144	performed the variable selection as described below and subsequently included the selected metabolites in a multivariable logistic regression model. Due to the correlated
142 143 144 145	performed the variable selection as described below and subsequently included the selected metabolites in a multivariable logistic regression model. Due to the correlated nature of the markers, we considered pairwise correlations between the metabolic
142 143 144 145 146	performed the variable selection as described below and subsequently included the selected metabolites in a multivariable logistic regression model. Due to the correlated nature of the markers, we considered pairwise correlations between the metabolic biomarkers from MEC (Supplement Table 1). For the set of T2D associated metabolic
142 143 144 145 146 147	performed the variable selection as described below and subsequently included the selected metabolites in a multivariable logistic regression model. Due to the correlated nature of the markers, we considered pairwise correlations between the metabolic biomarkers from MEC (Supplement Table 1). For the set of T2D associated metabolic biomarkers in the association analysis above that considered a metabolic biomarker
142 143 144 145 146 147 148	performed the variable selection as described below and subsequently included the selected metabolites in a multivariable logistic regression model. Due to the correlated nature of the markers, we considered pairwise correlations between the metabolic biomarkers from MEC (Supplement Table 1). For the set of T2D associated metabolic biomarkers in the association analysis above that considered a metabolic biomarker individually across Asian and European populations, we first sorted the metabolic
142 143 144 145 146 147 148 149	performed the variable selection as described below and subsequently included the selected metabolites in a multivariable logistic regression model. Due to the correlated nature of the markers, we considered pairwise correlations between the metabolic biomarkers from MEC (Supplement Table 1). For the set of T2D associated metabolic biomarkers in the association analysis above that considered a metabolic biomarker individually across Asian and European populations, we first sorted the metabolic biomarkers by their strength of association. Starting with the most significantly
142 143 144 145 146 147 148 149 150	performed the variable selection as described below and subsequently included the selected metabolites in a multivariable logistic regression model. Due to the correlated nature of the markers, we considered pairwise correlations between the metabolic biomarkers from MEC (Supplement Table 1). For the set of T2D associated metabolic biomarkers in the association analysis above that considered a metabolic biomarker individually across Asian and European populations, we first sorted the metabolic biomarkers by their strength of association. Starting with the most significantly associated metabolic biomarker (index-associated metabolic biomarker), we

154	association with T2D and pairwise correlations <0.80. Finally, we performed stepwise
155	regression analysis with the criterion of <i>P</i> -value of 0.05 in a joint model that included
156	the selected biomarkers in the Asian and European cohorts. All statistical analyses
157	were conducted using R 3.3.2 (R Foundation for Statistical Computing, Vienna,
158	Austria).
159	
160	Results
161	In the nested MEC case-control study, 694 incident T2D cases and 1315 matched
162	controls were included in this study during a mean follow-up of 6.9 y (standard
163	deviation SD: 2.4 y), and in the SEED cohort study, 391 incident T2D cases occurred
164	in 4384 participants during an average of 6.2 y (SD: 1.1 y). In the European cohorts,
165	1055 incident T2D cases occurred in 14,558 participants during an average of 11.3
166	years (SD: 5.0 y). The average age was 54.0 y (SD: 9.8 y) for the Asian participants
167	and 50.6 y (SD: 14.1 y) for the European participants, with similar representation of
168	males and females for all populations, and Chinese, Malays and Indians for the Asian
169	population (Table 1).
170	
171	We observed high correlations among the branched-chain amino acids (BCAAs)
172	leucine, isoleucine and valine, and concentrations of n-6 polyunsaturated (n-6 PUFA)
173	fatty acids, PUFA, monounsaturated fatty acids (MUFA), saturated fatty acids and
174	linoleic acid (18:2n-6) (all r>0.80) (Supplemental Tables 1 to 4). In general, the lipid
175	components (total lipids, phospholipids, cholesterol esters, free cholesterol) with the
176	exception of triglycerides within a particular lipoprotein subclass were also highly
177	correlated. Overall, 59 of the 154 metabolic biomarkers were consistently associated
178	with a higher risk and 13 with a lower risk of T2D in both Asians and Europeans

11

179	($P_{meta} < 0.0003$; Bonferroni-corrected; $P_{het} < 0.05$ for 12 metabolic biomarkers)
180	(Table 2, Figure 1 and Supplemental Table 5) after adjustment for age, sex, BMI
181	and either fasting glucose or HbA1c. For the population-specific meta-analysis, we
182	observed little heterogeneity in association across the three Asian ethnic groups ($P_{het} \ge$
183	0.05 for all 154 metabolic biomarkers) and across the three European cohorts ($P_{het} \ge$
184	0.05 for 144 of 154 metabolic biomarkers). Of the 29 metabolic biomarkers for which
185	we did observe evidence for heterogeneity between the Asian and European
186	populations, 23 were lipoprotein measures.
187	
188	Amino Acids and Inflammation
189	Higher concentrations of BCAAs (leucine, isoleucine, and valine), aromatic amino
190	acids (phenylalanine and tyrosine), and alanine were significantly and consistently
191	associated with higher T2D risk in both Asians and Europeans (all $P_{het} > 0.05$). The
192	strongest association was observed for leucine (Asians: OR 1.50 per 1 SD increment,
193	95% CI 1.35 - 1.66; Europeans: OR 1.36, 95% CI 1.27 - 1.46). The inflammatory
194	marker glycoprotein acetyls (GlycA) was also directly associated with risk of T2D
195	(Asians: OR 1.41, 95% CI 1.28 - 1.55; Europeans: OR 1.34, 95% CI 1.25 - 1.43; P _{het}
196	= 0.37). GlycA remained directly associated with T2D risk after further adjustments
197	for CRP (data available only for MEC and the European cohorts, Asians: OR 1.94,
198	95% CI 1.63 - 2.31; Europeans: OR 1.34, 95% CI 1.25 - 1.44).
199	
200	Fatty Acids
201	Higher total concentrations of fatty acids were significantly associated with higher
202	T2D risk. Among the different types of fatty acids, a higher proportion of MUFA was

203 consistently associated with a higher T2D risk (Asians: OR 1.43, 95% CI 1.30 - 1.57;

204	Europeans: OR 1.38, 95% CI 1.27 - 1.51), and a higher proportion of n-6 PUFA with
205	a lower risk (Asians: OR 0.70, 95% CI 0.64 - 0.77; Europeans: OR 0.70, 95% CI 0.65
206	- 0.75). The proportion of saturated fat (SFA) was directly associated with T2D risk,
207	but this was not statistically significant after Bonferroni correction in Asians (Asians:
208	OR 1.15, 95% CI: 1.05 - 1.25; Europeans: OR 1.21, 95% CI 1.13 - 1.29). n-3 PUFAs
209	were not significantly associated with risk of T2D in any ethnic group. There was no
210	evidence of heterogeneity for associations of fatty acids with T2D between the Asian
211	and European populations (all $P_{het} > 0.05$).
212	
213	Lipoprotein Measures
214	We evaluated lipoprotein particle sizes, apolipoproteins and various lipoprotein
215	measures including total concentrations, total lipids, phospholipids, total cholesterol,
216	cholesterol esters, free cholesterol and triglycerides for 14 lipoprotein subclasses, in
217	relation to T2D (Figure 1 and Supplemental Table 5).
218	
219	
219	Higher levels of apolipoprotein B were associated with higher T2D risk in both
220	Higher levels of apolipoprotein B were associated with higher T2D risk in both Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30;
220	Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30;
220 221	Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30; $P_{\text{het}} = 0.45$). Larger VLDL particle size was among the metabolic biomarkers with the
220 221 222	Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30; $P_{het} = 0.45$). Larger VLDL particle size was among the metabolic biomarkers with the strongest direct associations with T2D risk (Asians: OR 1.44, 95% CI 1.31 - 1.59;
220 221 222 223	Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30; $P_{het} = 0.45$). Larger VLDL particle size was among the metabolic biomarkers with the strongest direct associations with T2D risk (Asians: OR 1.44, 95% CI 1.31 - 1.59; Europeans: OR 1.46, 95% CI 1.36 - 1.57; $P_{het} = 0.83$). Larger LDL particle sizes were
220 221 222 223 224	Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30; $P_{het} = 0.45$). Larger VLDL particle size was among the metabolic biomarkers with the strongest direct associations with T2D risk (Asians: OR 1.44, 95% CI 1.31 - 1.59; Europeans: OR 1.46, 95% CI 1.36 - 1.57; $P_{het} = 0.83$). Larger LDL particle sizes were inversely associated with incident T2D risk in Europeans (OR 0.82, 95% CI 0.76 -
220 221 222 223 224 225	Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30; $P_{het} = 0.45$). Larger VLDL particle size was among the metabolic biomarkers with the strongest direct associations with T2D risk (Asians: OR 1.44, 95% CI 1.31 - 1.59; Europeans: OR 1.46, 95% CI 1.36 - 1.57; $P_{het} = 0.83$). Larger LDL particle sizes were inversely associated with incident T2D risk in Europeans (OR 0.82, 95% CI 0.76 - 0.89), but not in Asians (Asians: OR 0.98, 95% CI 0.89 - 1.07; $P_{het} = 0.01$). Larger

229

230	The concentration of cholesterol in very low-density lipoprotein (VLDL) particles
231	was generally associated with higher risk of T2D in both Asians and Europeans (all
232	$P_{\text{het}} > 0.05$), with the strongest association observed for cholesterol in large VLDL
233	particles (Asians: OR 1.41, 95% CI 1.29 - 1.53; Europeans: OR 1.29, 95% CI 1.22 -
234	1.37; $P_{\text{het}} = 0.10$). Because the lipid components (total lipids, phospholipids,
235	cholesterol esters, free cholesterol, triglycerides) in VLDL particles were highly
236	correlated (Supplemental Tables 1 to 4), particularly in extremely large VLDL, very
237	large VLDL, large VLDL and medium VLDL (Pearson's r>0.85), these lipid
238	components were similarly associated with T2D risk as VLDL cholesterol.
239	
240	Total high-density lipoprotein (HDL) cholesterol was inversely associated with T2D
241	risk in Asians (OR 0.85, 95% CI 0.76 - 0.94) and Europeans (OR 0.76, 95% CI 0.69 -
242	0.82; $P_{\text{het}} = 0.09$), although this did not reach Bonferroni-corrected significance in
243	Asians. These inverse associations appeared to be driven by cholesterol in very large
244	and large HDL particles, which were stronger in Europeans than in Asians (very large
245	HDL: $P_{het}=0.02$; large HDL: $P_{het}=0.04$). Other lipid components of HDL (total lipids,
246	phospholipids, cholesterol esters, free cholesterol) with the exception of triglycerides
247	were similarly associated with T2D risk as the cholesterol component of HDL. There
248	were no significant associations between intermediate-density lipoprotein (IDL)
249	cholesterol and low-density lipoprotein (LDL) cholesterol concentrations and T2D
250	risk.
251	
252	Elevated concentrations of total triglycerides were significantly associated with a

253 higher risk of T2D in Asians (OR 1.43, 95% 1.31 - 1.57) and Europeans (OR 1.32,

254	95% CI 1.25 - 1.40; $P_{\text{het}} = 0.14$). Results were similar when we analyzed triglycerides
255	in subclasses of VLDL, LDL, and HDL, with the exception of triglycerides in large
256	HDL.
257	
258	Other Metabolic Biomarkers
259	We also evaluated ketone bodies, glycerides, phospholipids, and metabolites related
260	to glycolysis and fluid balance (Table 2). Higher phosphoglyceride concentrations
261	were associated with T2D risk but this remained significant after Bonferroni
262	correction only in Asians (OR 1.18, 95% CI 1.08 - 1.30) and not in Europeans (OR
263	1.08, 95% CI 1.01, 1.16; $P_{\text{het}} = 0.14$). Similarly, higher albumin concentrations were
264	significantly associated with a higher risk of T2D in Asians (OR 1.23, 95% CI: 1.12 -
265	1.35), but not Europeans (OR 1.12, 95% CI 0.97 - 1.28; $P_{\text{het}} = 0.25$).
266	
267	Joint Effects of Metabolic Biomarkers on Risk of T2D
268	Using the correlation-pruning method, 12 metabolic biomarkers in MEC were
269	significantly associated with T2D with pairwise correlations with all other biomarkers
269 270	
	significantly associated with T2D with pairwise correlations with all other biomarkers
270	significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA,
270 271	significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA, unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small
270 271 272	significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA, unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small VLDL particle concentration, and very large HDL phospholipids. Stepwise regression
270 271 272 273	significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA, unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small VLDL particle concentration, and very large HDL phospholipids. Stepwise regression selected a multivariable model that simultaneously included isoleucine, GlycA,
270 271 272 273 274	significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA, unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small VLDL particle concentration, and very large HDL phospholipids. Stepwise regression selected a multivariable model that simultaneously included isoleucine, GlycA, unsaturation index, and very large HDL phospholipids (Supplemental Table 6).
270 271 272 273 274 275	significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA, unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small VLDL particle concentration, and very large HDL phospholipids. Stepwise regression selected a multivariable model that simultaneously included isoleucine, GlycA, unsaturation index, and very large HDL phospholipids (Supplemental Table 6). Higher levels of isoleucine (Asians: OR 1.25, 95% CI 1.10 - 1.42; Europeans: 1.18,
270 271 272 273 274 275 276	significantly associated with T2D with pairwise correlations with all other biomarkers <0.80. These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA, unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small VLDL particle concentration, and very large HDL phospholipids. Stepwise regression selected a multivariable model that simultaneously included isoleucine, GlycA, unsaturation index, and very large HDL phospholipids (Supplemental Table 6). Higher levels of isoleucine (Asians: OR 1.25, 95% CI 1.10 - 1.42; Europeans: 1.18, 95% CI 1.06 - 1.31) and GlycA (Asians: OR 1.17, 95% CI 1.03 - 1.33; Europeans:

279	Europeans: OR 0.70, 95% CI 0.62 - 0.78). There was no independent significant
280	association between unsaturation index and T2D risk. We observed evidence of
281	heterogeneity between the Asian and European populations only for very large HDL
282	phospholipids ($P_{\text{het}} = 0.01$).
283	
284	Discussion
285	We quantified 154 metabolic biomarkers using NMR technology in plasma and serum
286	samples from five prospective cohort studies representing three major ethnic groups
287	in Asia (Chinese, Malay, and Indian) and a European population. While there have
288	been previous metabolomics studies in Asians and individuals of European descent,
289	these were mostly conducted separately in ethnically homogenous populations with
290	cross-sectional study design, different metabolomics platforms or statistical methods
291	that did not facilitate direct comparison of results [13, 25]. Here, we report that
292	branched-chain amino acids, aromatic amino acids, alanine, the inflammatory marker
293	GlycA, total fatty acids, the proportion of MUFA, apolipoprotein B, larger VLDL
294	particle sizes and triglycerides were consistently associated with a higher T2D risk in
295	Asians and Europeans. Furthermore, the proportion of n-6 PUFA and larger HDL
296	particle sizes were consistently associated with a lower T2D risk in Asians and
297	Europeans. Overall, associations were consistent across the Asian ethnic groups, and
298	largely consistent for the Asian and European populations.
299	
300	Our finding that higher concentrations of BCAAs (leucine, isoleucine and valine)
301	were associated with a higher risk of T2D is consistent with the results of previous
302	prospective studies [13, 23, 25-30]. Results from Mendelian randomization studies
303	suggest that BCAA metabolites play a causal role in the pathogenesis of T2D [30]. In

16

304	line with our results, the aromatic amino acids phenylalanine and tyrosine were
305	directly associated with T2D risk in a meta-analysis of prospective studies [13], and
306	alanine was directly associated with T2D risk in a Japanese cohort [27]. Elevated
307	concentrations of aromatic amino acids and alanine have been hypothesized to induce
308	insulin resistance, possibly by inhibition of glucose transport and phosphorylation in
309	skeletal muscle [13, 31, 32].
310	
311	A higher concentration of the inflammatory marker GlycA was associated with a
312	higher risk of T2D in our study, which is compatible with results from the Dutch
313	PREVEND study and the U.S. Women's Health Study [33, 34]. GlycA is a composite
314	NMR measure that arises from the N-acetyl methyl group protons of oligosaccharide
315	moieties of acute-phase proteins [35], proteins whose concentrations change in
316	response to inflammation. As opposed to CRP, which is characterized by multi-fold
317	elevation in acute state, GlycA levels fluctuate less on short-term bases and may
318	therefore capture different aspects of the inflammatory response [36], a hypothesis
319	supported by our results and results of the PREVEND study as GlycA remains
320	directly associated with T2D risk after adjusting for CRP [33]. However, in the
321	Women's Health Study, the association between GlycA and incident T2D was
322	significantly attenuated after adjusting for CRP [34]. It is plausible that low-grade
323	inflammation is involved in the pathogenesis of T2D through insulin resistance and
324	beta-cell dysfunction [37, 38].
325	
326	Our report of a direct association between circulating MUFA and T2D risk is
0.07	

327 consistent with a previous finding in a Finnish cohort [39], but not with the

328 Atherosclerosis Risk in Communities (ARIC) study [40]. Because MUFA can be

17

329	synthesized endogenously from SFA [41], MUFAs concentrations may reflect SFA
330	intake. We also observed a direct association between circulating SFA and T2D risk
331	although this was not significant in Asians. In the ARIC study [40] and a Finnish
332	cohort [39], a higher proportion of SFA was also associated with higher T2D risk. It
333	has been hypothesized that high SFA concentrations promote insulin resistance and
334	are lipotoxic to beta-cells [42, 43]. Our study further showed that higher proportions
335	of n-6 PUFAs were associated with a lower risk of T2D, concordant with a previous
336	meta-analysis of prospective cohort studies [44]. The association may be partly
337	mediated by increasing insulin sensitivity through increasing cellular membrane
338	fluidity [45, 46], particularly of skeletal muscle cells and hepatocytes [45, 46], and by
339	acting as ligands for peroxisome proliferator-activated receptor gamma [47, 48].
340	These hypotheses are supported by a meta-analysis of randomized feeding trials that
341	showed improvements in glucose-insulin homeostasis for dietary PUFA compared to
342	SFA or MUFA [49]. In a recent Mendelian randomization study, genetic
343	predisposition to higher levels of linoleic acid was associated with a lower risk of
344	T2D [50], supporting a causal effect of linoleic acid on T2D. The lack of association
345	between the relative fraction of n-3 PUFA and T2D risk is consistent with a previous
346	meta-analysis of prospective studies [51].
347	
348	We also identified several patterns in the lipoprotein profile that were consistently

associated with T2D risk across ethnic groups. Larger VLDL particles were directly
associated with T2D risk, similar to existing evidence from prospective studies [23,
52-54]. VLDL is mostly comprised of triglycerides, and larger particles carry more
triglycerides [54]. The causal relationship between circulating triglycerides and T2D
is still a matter of debate [55] and there was no consensus among studies on

354	genetically influenced triglyceride levels and T2D incidence [56, 57]. Our finding that
355	the concentration of larger HDL particles was inversely associated with T2D risk also
356	agrees with previous prospective studies in western populations [23, 52-54]. While
357	HDL lipid components (e.g. phospholipids, cholesterol esters, free cholesterol) in very
358	large and large HDL particles were associated with lower risk of T2D, they were not
359	associated with T2D risk in medium and small HDL particles. This suggests that the
360	inverse associations observed for HDL lipid components were driven by particle size
361	rather than lipid composition. Larger HDL particles have been hypothesized to be
362	more efficient in cholesterol efflux capacity than smaller HDL particles [58, 59]. HDL
363	particles may also have other anti-diabetic properties such as promoting insulin
364	secretion and glucose uptake in skeletal muscle cells [60].
365	
366	Our study's strengths included the use of large population-based cohorts collected in
366 367	Our study's strengths included the use of large population-based cohorts collected in diverse populations with reasonable follow-up times that allowed us to have sufficient
367	diverse populations with reasonable follow-up times that allowed us to have sufficient
367 368	diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for
367 368 369	diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for heterogeneity between populations. However, we also acknowledge certain
367 368 369 370	diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for heterogeneity between populations. However, we also acknowledge certain limitations. First, a limitation of NMR technology compared to mass spectrometry is
367 368 369 370 371	diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for heterogeneity between populations. However, we also acknowledge certain limitations. First, a limitation of NMR technology compared to mass spectrometry is its lower sensitivity, and we could not quantify metabolic biomarkers that were below
367 368 369 370 371 372	diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for heterogeneity between populations. However, we also acknowledge certain limitations. First, a limitation of NMR technology compared to mass spectrometry is its lower sensitivity, and we could not quantify metabolic biomarkers that were below the detection limit of NMR. Second, participants of the SEED cohorts were not
367 368 369 370 371 372 373	diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for heterogeneity between populations. However, we also acknowledge certain limitations. First, a limitation of NMR technology compared to mass spectrometry is its lower sensitivity, and we could not quantify metabolic biomarkers that were below the detection limit of NMR. Second, participants of the SEED cohorts were not required to fast and this may have affected levels of certain metabolic biomarkers
367 368 369 370 371 372 373 374	diverse populations with reasonable follow-up times that allowed us to have sufficient statistical power to evaluate the associations separately in each ethnic group and for heterogeneity between populations. However, we also acknowledge certain limitations. First, a limitation of NMR technology compared to mass spectrometry is its lower sensitivity, and we could not quantify metabolic biomarkers that were below the detection limit of NMR. Second, participants of the SEED cohorts were not required to fast and this may have affected levels of certain metabolic biomarkers such as triglycerides and amino acids [61, 62]. However, this would have more likely

378	obtained consistent results across the different cohorts. Finally, we cannot rule out
379	residual confounding due to unmeasured or imperfectly measured risk factors.
380	
381	Our results may have implications in clinical practice, including the prevention and
382	treatment, and early detection and prognosis of T2D. The metabolic biomarkers
383	associated with T2D risk in our study are modifiable and may thus provide targets for
384	lifestyle and pharmacological interventions for prevention and treatment. For
385	example, replacing dietary SFA with PUFA has long been part of dietary
386	recommendation to reduce cardiovascular disease risk [63] and may also reduce T2D
387	risk by improving plasma fatty acid profiles. Similarly, dietary BCAAs and aromatic
388	amino acids are primarily from animal products, such as meat, and lower consumption
389	may reduce T2D risk partly by improving circulating amino acids [64-66] and insulin
390	sensitivity [67]. Furthermore, cholesteryl ester transfer protein inhibitors are a drug
391	class that is known to preferentially increase larger HDL particles [68, 69]. In a meta-
392	analysis of four randomized trials, these drugs significantly reduced T2D risk
393	although it is unclear if this effect is caused solely by changes in circulating HDL [68-
394	70]. Because these metabolic biomarkers reflect modifiable pathways, metabolic
395	profiling data could inform 'precision medicine' approaches that prioritize specific
396	preventive interventions for individuals at high risk of T2D. Various biomarkers such
397	as BCAAs and aromatic amino acids may be etiologically involved in insulin
398	resistance [31, 71], and the inclusion of these biomarkers to prediction models of T2D
399	improved area under curve (AUC) [72]. As the biological pathways involved in the
400	pathogenesis of T2D appear to be similar in Asians and Europeans, these
401	interventions and approaches for detection and prediction may be effective for both
402	populations.

20

404	Several physiological differences have been proposed to contribute to the higher
405	susceptibility to developing T2D in Asians than Europeans [7]. For example, greater
406	visceral adiposity and less lean body mass may contribute to the higher rates of T2D
407	in South Asians as compared with European ancestry populations [7, 73, 74]. The
408	generally consistent associations for metabolic biomarkers across diverse ethnic
409	groups in our study suggest that differences in the degree of metabolic disturbances in
410	the evaluated pathways rather than differences in the pathways involved contribute to
411	ethnic differences in risk of T2D. However, there may be exceptions for selected
412	biological pathways. For example, South Asians have been found to have smaller
413	mean HDL particle sizes as compared with European ancestry populations [75] and
414	this may contribute to the higher risk of T2D in South Asians through less efficient
415	reverse cholesterol transport and dyslipidemia [58]. Our observation of possibly
416	stronger inverse associations between HDL and T2D risk in Europeans than Asians,
417	particularly for very large HDL, is novel and warrants further studies.
418	
419	We found consistent associations between metabolic signatures and risk of T2D in
420	prospective cohorts in Asia and Europe. Metabolic aberrations that spanned multiple
421	pathways, including amino acids, inflammation, fatty acids and lipoproteins were
422	similarly associated with T2D risk in major Asian ethnic groups and Europeans
423	despite environmental, lifestyle, and physiological differences. Our results suggest
424	that these are candidates for better prediction of T2D in different ethnic groups that
425	require further evaluation in prognostic studies. Moreover, these metabolic
426	biomarkers are modifiable and may be targets for preventive interventions across

427	different ethnic groups.	Metabolic profiles ma	y inform future	personalized

- 428 interventions for the prevention of T2D in increasingly cosmopolitan populations.
- 429

430 Acknowledgements

- 431 All authors have no conflicts of interest.
- 432

433 CS, SN, TYW, C-YC, PJ, AL, MP, VS, EST, PW, RMvD and XS and conceived and

434 designed research. AC and PW conducted experiments. CS, SN, TYW, C-YC, PJ,

435 AL, MP, VS, EST, PW and RMvD contributed data. JYHS, YH, AC and XS analyzed

- 436 data. JYHS, RMvD and XS wrote the manuscript and had primary responsibility for
- 437 final content. All authors read and approved the manuscript.
- 438
- 439 The authors thank all investigators, staff members, and study participants for their

440 contributions to all the participating studies. The MEC is supported by grants from the

441 Singapore Ministry of Health, including National Medical Research Council Large

442 Collaborative Grant (MOH-000271-00), National University of Singapore and

- 443 National University Health System, Singapore. Metabolic profiling for MEC was
- supported by NUHS Summit Research Program (Metabolic Diseases) and performed
- by Nightingale Health Ltd. The SEED cohorts are supported by the National Medical
- 446 Research Council (NMRC), Singapore (grants 0796/2003, 1176/2008, 1149/2008,
- 447 STaR/0003/2008, 1249/2010, CG/SERI/2010, CIRG/1371/2013, CIRG/1417/2015,
- 448 CIRG/1488/2018 and OFLCG/004a/2018), and Biomedical Research Council
- 449 (BMRC), Singapore (08/1/35/19/550 and 09/1/35/19/616). VS was supported by the
- 450 Finnish Foundation for Cardiovascular Research. JYHS was supported by the

22

451 Si	ngapore Ministry	of Health's	National I	Medical	Research	Council Large)
--------	------------------	-------------	------------	---------	----------	---------------	---

- 452 Collaborative Grant (MOH-000271-00).
- 453

454 Disclosures

- 455 A. Cichońska and P. Wu Trtz are employees and shareholders of Nightingale
- 456 Health Ltd., a company offering NMR-based biomarker profiling.
- 457 B. VS has received honoraria for consulting for Novo Nordisk and Sanofi. He
- 458 also has ongoing research collaboration with Bayer Ltd (All unrelated to the
- 459 present study).
- 460

461 **Data availability**

- 462 Data described in the manuscript, code book and analytic code will be made available
- 463 upon request pending application and approval.

References

- Nanditha, A., et al., *Diabetes in Asia and the Pacific: Implications for the Global Epidemic*. Diabetes Care, 2016. **39**(3): p. 472-485.
- Khan, M.A.B., et al., *Epidemiology of Type 2 Diabetes Global Burden of Disease and Forecasted Trends*. Journal of Epidemiology and Global Health, 2020. 10(1): p. 107-111.
- Uusitupa, M., et al., Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis. Nutrients, 2019. 11(11).
- Gillies, C.L., et al., *Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.* British Medical Journal, 2007. 334(7588): p. 299-302B.
- Sheng, Z., et al., Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2019. 10.
- Kodama, K., et al., *Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response A systematic review and meta-analysis*.
 Diabetes Care, 2013. 36(6): p. 1789-1796.
- Chan, J.C.N., et al., *Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology*. Jama-Journal of the American Medical Association, 2009.
 301(20): p. 2129-2140.
- Philipson, L.H., *Harnessing heterogeneity in type 2 diabetes mellitus*. Nature Reviews Endocrinology, 2020. 16(2): p. 79-80.

- Prasad, R.B. and L. Groop, *Precision medicine in type 2 diabetes*. Journal of Internal Medicine, 2019. 285(1): p. 40-48.
- Palmnäs, M., et al., Perspective: Metabotyping-A Potential Personalized Nutrition Strategy for Precision Prevention of Cardiometabolic Disease. Adv Nutr, 2020. 11(3): p. 524-532.
- 11. Wishart, D.S., *Emerging applications of metabolomics in drug discovery and precision medicine*. Nature Reviews Drug Discovery, 2016. **15**(7): p. 473-484.
- Putri, S.P., et al., *Current metabolomics: Technological advances*. Journal of Bioscience and Bioengineering, 2013. **116**(1): p. 9-16.
- Guasch-Ferre, M., et al., *Metabolomics in Prediabetes and Diabetes: A* Systematic Review and Meta-analysis. Diabetes Care, 2016. **39**(5): p. 833-846.
- Gao, H., et al., *Can body fat distribution, adiponectin levels and inflammation explain differences in insulin resistance between ethnic Chinese, Malays and Asian Indians?* International Journal of Obesity, 2012. 36(8): p. 1086-1093.
- 15. Markley, J.L., et al., *The future of NMR-based metabolomics*. Current Opinion in Biotechnology, 2017. **43**: p. 34-40.
- Marshall, D.D. and R. Powers, *Beyond the paradigm: Combining mass* spectrometry and nuclear magnetic resonance for metabolomics. Progress in Nuclear Magnetic Resonance Spectroscopy, 2017. 100: p. 1-16.
- Tan, K.H.X., et al., Cohort Profile: The Singapore Multi-Ethnic Cohort (MEC) study. Int J Epidemiol, 2018.
- Lavanya, R., et al., Methodology of the Singapore Indian Chinese Cohort (SICC) Eye Study: Quantifying ethnic variations in the epidemiology of eye diseases in Asians. Ophthalmic Epidemiology, 2009. 16(6): p. 325-336.

- 19. Rosman, M., et al., *Singapore Malay Eye Study: rationale and methodology of*6-year follow-up study (SiMES-2). Clinical and Experimental Ophthalmology,
 2012. 40(6): p. 557-568.
- 20. Borodulin, K., et al., *Cohort Profile: The National FINRISK Study*. International Journal of Epidemiology, 2018. **47**(3): p. 696-+.
- 21. Pirkola, S.P., et al., DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population Results from the Health 2000 Study. Social Psychiatry and Psychiatric Epidemiology, 2005. 40(1): p. 1-10.
- 22. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care, 2020. 43(Suppl 1): p. S14-s31.
- Ahola-Olli, A.V., et al., *Circulating metabolites and the risk of type 2* diabetes: a prospective study of 11,896 young adults from four Finnish cohorts. Diabetologia, 2019. 62(12): p. 2298-2309.
- Soininen, P., et al., Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. Circulation-Cardiovascular Genetics, 2015. 8(1): p. 192-206.
- 25. Tillin, T., et al., Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study. Diabetologia, 2015. 58(5): p. 968-979.
- Flores-Guerrero, J.L., et al., *Plasma Branched-Chain Amino Acids and Risk of Incident Type 2 Diabetes: Results from the PREVEND Prospective Cohort Study*. Journal of Clinical Medicine, 2018. 7(12).

- 27. Chen, S.M., et al., Serum amino acid profiles and risk of type 2 diabetes among Japanese adults in the Hitachi Health Study. Scientific Reports, 2019.
 9.
- 28. Satheesh, G., S. Ramachandran, and A. Jaleel, *Metabolomics-Based Prospective Studies and Prediction of Type 2 Diabetes Mellitus Risks*. Metabolic Syndrome and Related Disorders, 2020. 18(1): p. 1-9.
- 29. Lu, Y.H., et al., *Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS*. Diabetologia, 2016. **59**(11): p. 2349-2359.
- Lotta, L.A., et al., Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. Plos Medicine, 2016. 13(11).
- 31. Wurtz, P., et al., *Branched-Chain and Aromatic Amino Acids Are Predictors* of Insulin Resistance in Young Adults. Diabetes Care, 2013. **36**(3): p. 648-655.
- 32. Krebs, M., et al., *Mechanism of amino acid-induced skeletal muscle insulin resistance in humans*. Diabetes, 2002. **51**(3): p. 599-605.
- Connelly, M.A., et al., *GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study.* Clinica Chimica Acta, 2016. 452: p. 10-17.
- 34. Akinkuolie, A.O., et al., Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol, 2015.
 35(6): p. 1544-50.
- 35. Connelly, M.A., et al., *GlycA*, *a novel biomarker of systemic inflammation and cardiovascular disease risk*. Journal of Translational Medicine, 2017. **15**.

- Ritchie, S.C., et al., *The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection*. Cell Systems, 2015. 1(4): p. 293-301.
- 37. Hameed, I., et al., *Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition*. World Journal of Diabetes, 2015. **6**(4): p. 598-612.
- Jin, C.C., J. Henao-Mejia, and R.A. Flavell, *Innate Immune Receptors: Key Regulators of Metabolic Disease Progression*. Cell Metabolism, 2013. 17(6):
 p. 873-882.
- Mahendran, Y., et al., Glycerol and Fatty Acids in Serum Predict the Development of Hyperglycemia and Type 2 Diabetes in Finnish Men. Diabetes Care, 2013. 36(11): p. 3732-3738.
- Wang, L., et al., *Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.*American Journal of Clinical Nutrition, 2003. 78(1): p. 91-98.
- 41. Nakamura, M.T. and T.Y. Nara, *Structure, function, and dietary regulation of Delta 6, Delta 5, and Delta 9 desaturases.* Annual Review of Nutrition, 2004.
 24: p. 345-376.
- 42. Oh, Y.S., et al., *Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes*. Frontiers in Endocrinology, 2018. 9.
- 43. Sobczak, A.I.S., C.A. Blindauer, and A.J. Stewart, *Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes*. Nutrients, 2019. **11**(9).
- Wu, J.H.Y., et al., Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. Lancet Diabetes & Endocrinology, 2017. 5(12): p. 965-974.

- 45. Kroger, J., et al., *Erythrocyte membrane fatty acid fluidity and risk of type 2 diabetes in the EPIC-Potsdam study*. Diabetologia, 2015. **58**(2): p. 282-289.
- Weijers, R.N.M., *Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus*. Current Diabetes Reviews, 2012. 8(5): p. 390-400.
- Lai, M.C., T.H. Teng, and C. Yang, *The Natural PPAR Agonist Linoleic Acid Stimulated Insulin Release in the Rat Pancreas*. Journal of Veterinary Medical Science, 2013. **75**(11): p. 1449-1454.
- 48. Echeverria, F., et al., Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging.
 Prostaglandins Leukotrienes and Essential Fatty Acids, 2016. 114: p. 28-34.
- Imamura, F., et al., Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled Feeding Trials. Plos Medicine, 2016. 13(7).
- 50. Yuan, S. and S.C. Larsson, Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study. Diabetologia, 2020. **63**(1): p. 116-123.
- 51. Wu, J.H.Y., et al., *Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis*. British Journal of Nutrition, 2012. 107:
 p. S214-S227.
- Mackey, R.H., et al., *Lipoprotein Particles and Incident Type 2 Diabetes in* the Multi-Ethnic Study of Atherosclerosis. Diabetes Care, 2015. 38(4): p. 628-636.

- 53. Hodge, A.M., et al., *NMR-determined lipoprotein subclass profile predicts type 2 diabetes*. Diabetes Research and Clinical Practice, 2009. 83(1): p. 132-139.
- 54. Mora, S., et al., *Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women*. Diabetes, 2010.
 59(5): p. 1153-1160.
- Hölzl, B., et al., *Hypertriglyceridemia and insulin resistance*. J Intern Med, 1998. 243(1): p. 79-82.
- 56. De Silva, N.M., et al., Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance. Diabetes, 2011. 60(3): p. 1008-18.
- 57. Qi, Q.B., et al., *Genetic Predisposition to Dyslipidemia and Type 2 Diabetes Risk in Two Prospective Cohorts.* Diabetes, 2012. **61**(3): p. 745-752.
- 58. Khera, A.V., et al., Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, 2017. 135(25): p. 2494-2504.
- Rysz, J., et al., *The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease*. International Journal of Molecular Sciences, 2020. 21(2).
- Drew, B.G., et al., *High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus*. Circulation, 2009. **119**(15): p. 2103-U134.

- 61. Jackson, K.G., S.D. Poppitt, and A.M. Minihane, *Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants.* Atherosclerosis, 2012. **220**(1): p. 22-33.
- Ottosson, F., et al., POSTPRANDIAL LEVELS OF BRANCH CHAINED AND AROMATIC AMINO ACIDS ASSOCIATED WITH FASTING GLYCAEMIA.
 Journal of Hypertension, 2016. 34: p. E145-E145.
- 63. Sacks, F.M., et al., Dietary Fats and Cardiovascular Disease A Presidential Advisory From the American Heart Association. Circulation, 2017. 136(3): p. E1-+.
- 64. Isanejad, M., et al., *Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women's Health Initiative*. British Journal of Nutrition, 2017.
 117(11): p. 1523-1530.
- Elshorbagy, A., et al., *Amino acid changes during transition to a vegan diet supplemented with fish in healthy humans*. European Journal of Nutrition, 2017. 56(5): p. 1953-1962.
- 66. Gunther, S.H., et al., *Diet, Physical Activity and Adiposity as Determinants of Circulating Amino Acid Levels in a Multiethnic Asian Population*. Nutrients, 2020. 12(9).
- 67. Karusheva, Y., et al., *Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: a randomized controlled crossover trial.* The American Journal of Clinical Nutrition, 2019. **110**(5): p. 1098-1107.
- 68. Krauss, R.M., et al., *Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.* Journal of Lipid Research, 2012. **53**(3): p. 540-547.

- 69. Kontush, A., *HDL particle number and size as predictors of cardiovascular disease*. Frontiers in Pharmacology, 2015. **6**.
- 70. Masson, W., et al., *Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk.* Diabetes & Metabolism, 2018. **44**(6): p. 508-513.
- Batch, B.C., et al., Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism, 2013. 62(7): p. 961-9.
- Gunther, S.H., et al., Serum acylcarnitines and amino acids and risk of type 2 diabetes in a multiethnic Asian population. BMJ Open Diabetes Res Care, 2020. 8(1).
- 73. Rush, E.C., I. Freitas, and L.D. Plank, Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr, 2009. 102(4): p. 632-41.
- Narayan, K.M.V. and A.M. Kanaya, *Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways*. Diabetologia, 2020.
 63(6): p. 1103-1109.
- 75. Bilen, O., A. Kamal, and S.S. Virani, *Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions.* World Journal of Cardiology, 2016. **8**(3): p. 247-257.

Legends for figures

Figure 1. Associations between baseline circulating lipoprotein measures and risk of incident type 2 diabetes. Values are ORs (95% CIs) per 1 SD increment in metabolic biomarkers levels. The results for Asian participants (n=6393) were meta-analysed using data from Chinese (n=2676), Malay (n=1872) and Indian (n=1845) participants of the MEC and the SEED cohorts which consist of the Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Results for the European participants (n=14558) were meta-analysed from 3 prospective Finnish cohorts (FINRISK 2002, FINRISK 2012 and Health 2000). We adjusted or matched for age, age² (only for MEC), sex, BMI and fasting glucose (MEC and Health 2000) or HbA1c (SEED cohorts, FINRISK 2002 and FINRISK 2012). We accounted for multiple testing using Bonferroni correction and P-values < 0.0003 were considered statistically significant. Abbreviations: ApoA1, apolipoprotein A1, ApoB, apolipoprotein B, HbA1c, glycated hemoglobin A1c, HDL, high-density lipoprotein, IDL, intermediate-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, SEED, Singapore Epidemiology of Eye Diseases, VLDL, very low-density lipoprotein

		MEC			SEED ²			European cohorts	
Characteristic	Chinese	Malay	Indian	Chinese	Malay	Indian	FINRISK 2002	FINRISK 2012	Health 2000
No. cases / No. controls	256/499	216/411	222/405	96/1825	132/1113	163/1055	350/3904	78/4475	627/6179
Follow-up duration (y)	7.4 ± 2.5	6.7 ± 2.5	6.6 ± 2.3	5.8 ± 0.9	7.1 ± 0.9	6.0 ± 0.9	13.8 ± 0.1	3.8 ± 0.1	15.1 ± 0.1
Age at interview (y)	53.6 ± 9.5	49.1 ± 9.9	47.8 ± 10.4	57 ± 8.6	54.8 ± 10	54.4 ± 8.4	48.5 ± 13.7	48.8 ± 13.8	53.2 ± 14.2
Male [n (%)]	356 (47.1)	234 (37.3)	257 (41)	889 (46.3)	563 (45.2)	568 (46.6)	1794 (45.9)	2088 (46.7)	2748 (44.5)
Education level ³									
Low	243 (32.2)	208 (33.2)	199 (31.8)	905 (47.1)	773 (62.2)	588 (48.4)	-	-	-
Intermediate	415 (55)	404 (64.5)	356 (56.9)	818 (42.6)	455 (36.6)	478 (39.3)	-	-	-
High	97 (12.8)	14 (2.2)	71 (11.3)	198 (10.3)	15 (1.2)	149 (12.3)	-	-	-
Body mass index (kg/m ²)	23.8 ± 3.7	26.9 ± 5	26.7 ± 4.9	23.4 ± 3.5	26 ± 4.7	25.7 ± 4.2	26.6 ± 4.5	26.6 ± 4.6	26.8 ± 4.6
Fasting glucose (mmol/L)	4.9 ± 0.6	5 ± 0.6	5.1 ± 0.6	-	-	-	-	-	5.4 ± 0.8
HbA1c $(\%)^4$	5.6 ± 0.4	5.6 ± 0.4	5.8 ± 0.4	5.8 ± 0.3	5.7 ± 0.4	5.7 ± 0.4	5.4 ± 0.4	5.2 ± 0.3	-
Total cholesterol (mmol/L)	5.3 ± 0.9	5.6 ± 1	5.3 ± 0.9	5.6 ± 1	5.7 ± 1.1	5.5 ± 1	5.6 ± 1.1	5.4 ± 1.0	6.0 ± 1.1
HDL cholesterol (mmol/L)	1.4 ± 0.3	1.3 ± 0.3	1.1 ± 0.3	1.4 ± 0.4	1.4 ± 0.3	1.1 ± 0.3	1.5 ± 0.4	1.5 ± 0.4	1.4 ± 0.4
LDL cholesterol (mmol/L)	3.4 ± 0.8	3.6 ± 0.9	3.5 ± 0.8	3.4 ± 0.9	3.6 ± 1	3.6 ± 0.8	3.4 ± 0.9	3.3 ± 0.9	3.8 ± 1.1

Table 1. Baseline characteristics of participants of the cohorts included in the study 1

All rights reserved. No reuse allowed without permission.	the author/funder, who has	101/2021.07.04.21259971; this version posted October 26, 2021. The co
---	----------------------------	---

Ę

34

Triglycerides (mmol/L)	1.2 (0.9,1.7)	1.2 (0.9,1.7)	1.3 (0.9,1.8)	1.4 (1.0,2.1)	1.3 (0.7,2.1)	1.6 (1.1,2.3)	1.1 (0.8, 1.6)	1.1 (0.8, 1.6)	1.3 (1.0, 1.8)	
DBP (mmHg)	78.7 ± 11.3	76.4 ± 11.7	74.5 ± 11.5	77.6 ± 9.9	79.2 ± 11.0	77.9 ± 10.1	78.7 ± 11.4	81.3 ± 11.1	82.0 ± 11.0	Jeinie
SBP (mmHg)	134.2 ± 20.6	131.9 ± 20	125.3 ± 21.4	133.4 ± 18.4	141 ± 22.3	130.9 ± 18.7	135.0 ± 20.2	132.7 ± 18.6	134.2 ± 20.7	u by pe
										_ a

¹Mean \pm SD; median (Q1, Q3)

² SEED cohorts consist of a collection of three cohorts: Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Participants of the SEED cohorts were not required to fast. LDL cholesterol was measured in the Singapore Chinese Eye Study and Singapore Indian Eye Study, and calculated in the Singapore Malay Eye Study.

³ We classified education level as follows: low – none, Primary or equivalent, intermediate – Secondary, diploma, Junior College, high school or equivalent, and high – college degree and above. The data for European cohorts could not be accessed.

⁴ Only a subset of participants in MEC (N = 598, 531, 516, for Chinese, Malay, and Indian) had HbA1c measurements. To convert HbA1c from % to mmol/mol, first multiply HbA1c (%) by 10.93 and then substract 23.50.

Abbreviations: DBP, diastolic blood pressure, HbA1c, glycated hemoglobin A1c, HDL, high-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, SEED, SBP, systolic blood pressure, Singapore Epidemiology of Eye Diseases, Q1, quantile 1, Q3, quantile 3

	Chinese	Malay	Indian	Meta-analys	is of Asians		Meta-analysis	of Europea	ns	P-het
Metabolite	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value	Р-	OR (95% CI)	P-value	Р-	(Asians a
						het			het	European
Branched-chain amino acids										0.14
Leucine	1.68 (1.41 - 2.00)	1.44 (1.19 - 1.73)	1.38 (1.16 - 1.64)	1.50 (1.35 - 1.66)	< 0.0003	0.26	1.36 (1.27 - 1.46)	< 0.0003	0.55	0.14
Isoleucine	1.68 (1.42 - 1.98)	1.43 (1.19 - 1.72)	1.33 (1.12 - 1.58)	1.48 (1.34 - 1.63)	< 0.0003	0.15	1.36 (1.27 - 1.45)	< 0.0003	0.76	0.17
Valine	1.54 (1.30 - 1.83)	1.35 (1.14 - 1.61)	1.36 (1.14 - 1.61)	1.42 (1.28 - 1.57)	< 0.0003	0.48	1.25 (1.16 - 1.35)	< 0.0003	0.39	0.05
Aromatic amino acids										
Phenylalanine	1.27 (1.07 - 1.51)	1.29 (1.04 - 1.59)	1.24 (1.04 - 1.47)	1.26 (1.14 - 1.40)	< 0.0003	0.96	1.22 (1.14 - 1.31)	< 0.0003	0.75	0.63
Tyrosine	1.34 (1.13 - 1.59)	1.21 (1.04 - 1.42)	1.22 (1.05 - 1.41)	1.25 (1.14 - 1.37)	< 0.0003	0.64	1.21 (1.13 - 1.29)	< 0.0003	0.79	0.56
Other amino acids										
Histidine	1.08 (0.91 - 1.27)	1.10 (0.91 - 1.32)	0.94 (0.80 - 1.11)	1.03 (0.93 - 1.14)	0.55	0.40	1.08 (1.00 - 1.16)	0.06	0.83	0.51
Alanine	1.35 (1.14 - 1.61)	1.15 (0.97 - 1.38)	1.27 (1.09 - 1.47)	1.26 (1.14 - 1.38)	< 0.0003	0.45	1.25 (1.14 - 1.39)	< 0.0003	0.19	0.96
Inflammation										
Glycoprotein acetyls	1.62 (1.38 - 1.90)	1.29 (1.05 - 1.58)	1.32 (1.15 - 1.52)	1.41 (1.28 - 1.55)	< 0.0003	0.11	1.34 (1.25 - 1.43)	< 0.0003	0.95	0.37
Fatty acids										


Table 2. Associations between non-lipoprotein metabolic biomarkers and type 2 diabetes¹


0.14 0.36 0.63 0.78
0.63 0.78
0.78
^{0.96} ≥
0.21 gnt
0.94 ese
0.75 Q
lo reu:
0.08 allo
0.14 a
0.09 OI
0.16 permi
0.25
0.25
0.00
0.82
0.01


											wa
Acetate	1.03 (0.84 - 1.27)	0.74 (0.50 - 1.10)	0.94 (0.81 - 1.09)	0.95 (0.85 - 1.06)	0.36	0.34	0.96 (0.88 - 1.05)	0.43	0.40	0.81	s not o
Acetoacetate	1.05 (0.91 - 1.22)	0.89 (0.74 - 1.07)	0.86 (0.73 - 1.02)	0.94 (0.86 - 1.04)	0.24	0.16	1.04 (0.96 - 1.12)	0.35	0.69	0.13	certifie
Albumin	1.28 (1.09 - 1.50)	1.26 (1.06 - 1.50)	1.17 (1.01 - 1.35)	1.23 (1.12 - 1.35)	< 0.0003	0.68	1.12 (0.97 - 1.28)	0.13	0.10	0.25	d by p
Creatinine	0.96 (0.75 - 1.23)	0.71 (0.56 - 0.92)	0.96 (0.80 - 1.15)	0.89 (0.78 - 1.01)	0.07	0.14	0.97 (0.84 - 1.13)	0.72	0.06	0.36	eer re
¹ Other than fatty acids and lipoprotein measures, results for all metabolic biomarkers are shown here. For individual fatty acids, we only showed fatty acids expressed as a percentage of total fatty $\mathbb{E}_{\mathbb{E}_{n}}^{\mathbb{E}_{n}}$											
acids to avoid confounding by total fatty acids. All results for lipoprotein measures are displayed in Figure 1. Estimates are odds ratios (95% confidence intervals) per SD increase. The results for											
Chinese (n=2676), Malay (n=1872) and Indian (n=1845) participants were meta-analysed from the MEC and the SEED cohorts which consist of the Singapore Chinese Eye Study, Singapore Mala											
Eye Study and the Singapore Indian Eye Study. Results for the European participants (n=14558) were meta-analysed from 3 prospective Finnish cohorts (FINRISK 2002, FINRISK 2012 and Heal B											
2000). We adjusted or matched for age, age2 (only for MEC), sex, BMI and fasting glucose (MEC and Health 2000) or HbA1c (SEED cohorts, FINRISK 2002, FINRISK 2012). We accounted for age											
multiple testing using Bonferroni correction and P-values < 0.0003 were considered statistically significant. P-het denotes Cochran Q heterogeneity.											
Abbreviations: HbA1c, glycated hemoglobin A1c, MEC, Multiethnic Cohort, MUFA, monounsaturated fatty acids, n-3, omega-3, n-6 - omega-6, PUFA, polyunsaturated fatty acids, SEED.											rant


Abbreviations: HbA1c, glycated hemoglobin A1c, MEC, Multiethnic Cohort, MUFA, monounsaturated fatty acids, n-3, omega-3, n-6 - omega-6, PUFA, polyunsaturated fatty acids, SEED, Singapore Epidemiology of Eye Diseases, SFA, saturated fatty acids











Odds ratio for incident type 2 diabetes (95% Cl) per 1–SD increment in metabolite concentration

Odds ratio for incident type 2 diabetes (95% Cl) per 1–SD increment in metabolite concentration